Market Overview

Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ (L-glutamine oral powder) to Military Personnel and Beneficiaries for Treatment of Sickle Cell Disease

Share:

Emmaus
Life Sciences
(Emmaus) announces it has entered into a distribution
agreement with DMS Pharmaceutical Group (DMS). The agreement makes
Endari available to patients represented by the U.S. Department of
Defense, which include three million active military personnel and 9.4
million beneficiaries.

DMS is a Park Ridge, Illinois-based pharmaceutical wholesale provider
and prime vendor supplier to the U.S. Department of Defense. DMS
supplies prescription and over-the-counter drugs to military base
treatment facilities, hospitals and medical clinics.

The agreement will provide distribution for Endari, the first
FDA-approved treatment for sickle cell disease in nearly 20 years, to
military personnel and beneficiaries with sickle cell disease.

"Our new partnership with DMS Pharmaceutical is an exciting step forward
as we strive to make Endari more available to patients who need it,"
said Yutaka Niihara, MD, MPH, CEO and founder of Emmaus Life Sciences.
"We're grateful for the opportunity to ensure that the men and women
serving our country, as well as their family members, have access to
Endari."

"DMS Pharmaceutical is pleased to collaborate with Emmaus on Endari as a
therapeutic treatment for our Department of Defense Military Treatment
Facilities' patients afflicted by sickle cell disease," said Sam Lazich,
President of DMS. "DMS' tag line – ‘Service is the Difference' – is the
cornerstone of the company's relationships with its customers – a theme
that continues to guide us. We do everything we can to provide
exceptional service to our customers. Our relationship with Emmaus
further strengthens our ability to serve our important military
customers and patients."

About Sickle Cell Disease

Sickle Cell Disease is an inherited blood disorder characterized by the
production of an altered form of hemoglobin which polymerizes and
becomes fibrous, causing red blood cells to become rigid and change form
so that they appear sickle shaped instead of soft and rounded. Patients
with Sickle Cell Disease suffer from debilitating episodes of sickle
cell crises, which occur when the rigid, adhesive and inflexible red
blood cells occlude blood vessels. Sickle cell crises cause excruciating
pain as a result of insufficient oxygen being delivered to tissue,
referred to as tissue ischemia, and inflammation. These events may lead
to a variety of other adverse outcomes such as acute chest syndrome that
requires hospitalization. Sickle cell disease is an orphan disease,
affecting approximately 100,000 patients in the U.S. and millions
worldwide with significant unmet medical needs.

About Endari™

Indication

Endari is indicated to reduce the acute complications of sickle cell
disease in adult and pediatric patients 5 years of age and older.

Important Safety Information

The most common adverse reactions (incidence >10%) in clinical studies
were constipation, nausea, headache, abdominal pain, cough, pain in
extremity, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included 1 case
each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and
hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell
disease younger than 5 years of age has not been established.

For more information, please see full Prescribing Information of Endari
at www.ENDARIrx.com/PI.

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the
discovery, development and commercialization of innovative treatments
and therapies primarily for rare and orphan disease. Its lead product,
Endari, demonstrated positive clinical results in the completed Phase 3
clinical trial for sickle cell anemia and sickle ß0-thalassemia and has
received FDA approval. Visit: http://www.emmausmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and potential commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. Additional risks and uncertainties are described
in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities
and Exchange Commission, including its Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Emmaus is providing this information as
of the date of this press release and does not undertake any obligation
to update any forward-looking statements as a result of new information,
future events or otherwise.

View Comments and Join the Discussion!